Jagsonpal Pharmaceuticals Ltd has announced its unaudited financial results for Q2 and H1FY26, showing a 10.2% revenue growth to 1,501 Mn and a 39.2% increase in PAT to 234 Mn compared to the same period last year. The results reflect stable performance despite GST adjustments and include the appointment of new executives.